Catalent, Inc. (NYSE:CTLT) Receives $63.40 Consensus Target Price from Analysts

Shares of Catalent, Inc. (NYSE:CTLT) have been given an average rating of “Hold” by the seven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a hold recommendation. The average 1-year price target among brokers that have covered the stock in the last year is $63.40.

A number of research analysts recently commented on the stock. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird reissued a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. StockNews.com began coverage on shares of Catalent in a report on Friday. They set a “hold” rating for the company. Finally, Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th.

Catalent Stock Performance

Shares of NYSE:CTLT opened at $63.48 on Friday. The stock has a market capitalization of $11.52 billion, a price-to-earnings ratio of -28.09, a PEG ratio of 2.70 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The company has a 50 day moving average price of $60.89 and a 200 day moving average price of $59.59. Catalent has a 1-year low of $41.15 and a 1-year high of $63.50.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the business earned ($0.10) earnings per share. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, research analysts anticipate that Catalent will post 0.78 EPS for the current fiscal year.

Insider Activity at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now directly owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Millennium Management LLC increased its position in shares of Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after purchasing an additional 2,299,784 shares during the last quarter. Bank of Montreal Can lifted its holdings in Catalent by 181.5% during the 3rd quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after purchasing an additional 1,169,044 shares during the last quarter. National Bank of Canada FI boosted its position in shares of Catalent by 300.0% in the third quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock valued at $88,481,000 after acquiring an additional 1,095,578 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Catalent by 166.5% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock valued at $83,733,000 after purchasing an additional 863,624 shares during the period. Finally, ING Groep NV boosted its stake in shares of Catalent by 162.5% in the third quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock valued at $68,475,000 after buying an additional 699,851 shares during the period.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.